Mitomycin as a Hyperthermic Peritoneal Perfusion in Treating Patients With Malignant Ascites

Stopped early · Phase 2

Conditions studied: Metastatic Cancer

In brief

RATIONALE: Hyperthermia therapy kills tumor cells by heating them to several degrees above normal body temperature. Peritoneal infusion of heated chemotherapy drugs, such as mitomycin, may kill more tumor cells. PURPOSE: This phase II trial is studying how well mitomycin works when given as a hyperthermic peritoneal perfusion in treating patients with malignant ascites.

Key facts

Study ID

NCT00265863

Run by

Masonic Cancer Center, University of Minnesota

People needed

1

Starts

2004-08-01

Expected to finish

2005-08-01

Last updated by the study team

2017-11-29

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of peritoneal metastases and malignant ascites by physical examination, ultrasound, or CT scan
• Not eligible for cytoreductive surgery based on any of the following criteria:
• Metastases outside peritoneal cavity
• Poor performance status
• Unresectable peritoneal disease
• Must have undergone at least 1 prior paracentesis procedure
• No ascites caused by any of the following conditions:
• Cardiac failure
• Nephrotic syndrome
• Pancreatic ascites
• Chylous ascites
• Eastern Cooperative Oncology Group (ECOG) performance status 0-3
• WBC ≥ 3,000/mm\^3
• Platelet count ≥ 70,000/mm\^3
• Bilirubin ≤ 2.0 mg/dL
• Creatinine ≤ 1.5 mg/dL
• Not pregnant or nursing
• Negative pregnancy test

You may not qualify if…

• Prior peritoneal chemotherapy
• Dense intraabdominal adhesions limiting laparoscopy

Where it is running

• University of Minnesota Cancer Center — Minneapolis, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.